Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | GPR17 | Q13304 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.38 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.38 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.38 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20253199 | 0.88 | POLB (0.50) | NPSR1GPR17POLBHPGDTSHR | |
| SCHEMBL19698994 | 0.86 | NPSR1 (0.52) | NPSR1GPR17POLBGRIA2FFAR1 | |
| SCHEMBL14793743 | 0.80 | CA2 (0.53) | POLBHPGDTSHRHSD17B10CA2 | |
| SCHEMBL5684993 | 0.80 | TRPV1 (0.52) | NPSR1POLBTSHRFFAR1 | |
| SCHEMBL2471781 | 0.79 | NPSR1 (0.46) | NPSR1GPR17HPGDTSHRHSD17B10 | |
| SCHEMBL8350554 | 0.77 | TSHR (0.52) | HPGDTSHRHSD17B10CA2 | |
| SCHEMBL1418003 | 0.77 | HIF1A (0.59) | NPSR1GPR17POLBHPGDHSD17B10 | |
| SCHEMBL32689799 | 0.77 | FFAR1 (0.49) | NPSR1GPR17TSHRFFAR1PLAU | |
| SCHEMBL30567601 | 0.77 | PDPK1 (0.59) | GPR17HPGDFFAR1PDPK1 | |
| SCHEMBL586345 | 0.77 | PDPK1 (0.59) | GPR17HPGDFFAR1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794576-A1 | NON-SYSTEMIC TGR5 AGONISTS | Ardelyx, Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013096771-A1 | NON-SYSTEMIC TGR5 AGONISTS | ARDELYX, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| EP-2370438-A1 | IMIDAZO [1,2A]PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION | Exelixis, Inc. (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| WO-2010065760-A1 | IMIDAZO [1,2A] PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION | EXELIXIS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | S1PR1, S1PR5, S1PR3 | NPSR1 39/4885GPR17 30/4885POLB 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.